The startup has developed a biotechnology platform that utilizes cryo-electron microscopy for structural analysis in drug discovery, enabling researchers to observe in-vivo structures without staining. This technology facilitates the identification and analysis of potential life-saving drugs by providing high-resolution insights into molecular structures.
Funding
$4.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery is often hindered by the inability to visualize the in-vivo structure of target proteins, limiting the understanding of drug interactions and impeding the development of effective therapeutics. Traditional methods often require staining, which can alter the native structure and introduce artifacts.
Solution
Curreio is a biotechnology company that leverages cryo-electron microscopy (cryo-EM) to provide high-resolution structural analysis for drug discovery. Their platform enables researchers to observe biomolecules in their native state, without the need for staining, providing detailed insights into protein structures and drug binding mechanisms. By visualizing previously inaccessible structures, Curreio facilitates the identification and analysis of potential drug candidates and accelerates the drug discovery process. The company has established proprietary techniques covering protein expression to structure determination, enabling a practical cryo-EM based drug discovery platform.
Target Audience
Curreio's primary customers are pharmaceutical companies and research institutions involved in drug discovery and development, particularly those focused on structure-based drug design.
Features
- Proprietary protein purification methods optimized for cryo-EM single-particle analysis.
- Specialized grid screening techniques applicable to diverse target proteins.
- Expertise in cryo-EM analysis of low molecular weight proteins.
- Integrated platform encompassing target protein expression and complex structure analysis.
- Application of computational chemistry and AI-driven drug discovery to enhance compound identification.
- Specializes in structural analysis of membrane proteins (GPCRs, Channels, Receptors), Kinases, and other protein families.